Zogenix transferred with a Buy at Stifel. Stifel transferred coverage of Zogenix to analyst Paul Matteis, who has a Buy rating and $69 price target on the stock. He views lead product ZX008 as a best-in-class anti-epileptic for Dravet Syndrome and places 65% odds of success on the ZX008 program in Lennox Gastaut Syndrome, Matteis tells investors.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.